Nisa Investment Advisors LLC Has $55,000 Stake in Inogen, Inc. (NASDAQ:INGN)

Nisa Investment Advisors LLC grew its holdings in shares of Inogen, Inc. (NASDAQ:INGNGet Rating) by 383.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,270 shares of the medical technology company’s stock after acquiring an additional 1,800 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Inogen were worth $55,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Inogen by 84,900.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,700 shares of the medical technology company’s stock worth $55,000 after purchasing an additional 1,698 shares during the last quarter. Walthausen & Co. LLC bought a new stake in shares of Inogen during the first quarter worth about $1,750,000. Factorial Partners LLC grew its holdings in shares of Inogen by 10.0% during the first quarter. Factorial Partners LLC now owns 32,000 shares of the medical technology company’s stock worth $1,037,000 after purchasing an additional 2,900 shares during the last quarter. Versor Investments LP bought a new stake in shares of Inogen during the first quarter worth about $381,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. grew its holdings in shares of Inogen by 100.0% during the first quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 40,000 shares of the medical technology company’s stock worth $1,297,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 97.65% of the company’s stock.

Inogen Stock Performance

Inogen stock opened at $20.19 on Thursday. The stock has a market capitalization of $462.77 million, a price-to-earnings ratio of -9.18 and a beta of 0.96. Inogen, Inc. has a 52-week low of $19.48 and a 52-week high of $37.17. The stock’s 50 day moving average price is $23.57 and its two-hundred day moving average price is $25.61.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Needham & Company LLC reduced their price target on Inogen from $45.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday, November 2nd. JPMorgan Chase & Co. reduced their target price on Inogen from $32.00 to $22.00 and set a “neutral” rating on the stock in a report on Thursday, November 3rd. Finally, StockNews.com began coverage on Inogen in a report on Wednesday, October 12th. They issued a “hold” rating on the stock.

Inogen Profile

(Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.